local_hospital

Hospital Universitario Fundacion Jimenez Diaz

Address
lock Available on a paid plan

Oncology and Hematologic Malignancies

At Hospital Universitario Fundacion Jimenez Diaz in Madrid, a major share of research focuses on neoplasms and blood cancers, with studies spanning non-small cell lung cancer, breast cancer, ovarian cancer, lymphoma, and multiple myeloma. These trials are largely designed to test new cancer treatments, combine therapies in smarter ways, and improve outcomes for patients with advanced or treatment-resistant disease.

  • Solid tumors including lung, breast, ovarian, colorectal, pancreatic, hepatobiliary, and gastrointestinal cancers
  • Lymphomas and other hematologic malignancies such as diffuse large B-cell lymphoma, mantle cell lymphoma, and multiple myeloma
  • Research aimed at evaluating immunotherapy, targeted treatment strategies, and treatment effectiveness in advanced cancer

The oncology portfolio is broad and highly active, reflecting the site’s strong role in studies of both common and rare cancers, with a clear emphasis on finding better options for people whose disease has progressed after standard care.

Cardiovascular and Renal Research

Cardiovascular studies at this site address conditions such as heart failure, acute myocardial infarction, and inherited risk for dilated cardiomyopathy, while renal research includes chronic kidney disease and focal segmental glomerulosclerosis. The main purpose is to improve prevention, protect organ function, and evaluate whether new approaches can reduce complications after major cardiac events or surgery.

  • Heart failure, acute decompensated heart failure, and post-infarction recovery
  • Genetic cardiomyopathy and strategies to prevent early disease progression
  • Kidney disease research focused on preserving renal function and reducing surgery-related injury

These studies combine disease prevention and treatment optimization, showing a strong interest in earlier intervention and better long-term outcomes for patients with cardiovascular and kidney disorders.

Neurology, Sleep, and Seizure Disorders

Research in nervous system diseases includes trials for epilepsy, focal onset seizures, chronic migraine, and glioblastoma, along with studies exploring sleep-related symptoms such as insomnia. The goal is to assess new therapies that may better control symptoms, reduce seizure burden, and improve daily functioning.

  • Epilepsy and focal seizures in adults and younger patients
  • Insomnia and sleep disturbance linked with other health conditions
  • Brain tumor research, especially glioblastoma, focused on improving treatment response

This area reflects a practical clinical focus on conditions that can strongly affect quality of life, with trials seeking safer and more effective ways to manage persistent neurological symptoms.

Digestive, Liver, and Inflammatory Disease Studies

The site also conducts research in digestive system diseases and immune-related conditions, including Crohn's disease, complex perianal fistulas, hepatocellular carcinoma, cholangiocarcinoma, and other gastrointestinal cancers. These studies aim to improve treatment options, support healing in inflammatory bowel disease, and evaluate new approaches for hard-to-treat liver and gastrointestinal malignancies.

  • Crohn's disease and associated fistulizing complications
  • Hepatobiliary cancers such as hepatocellular carcinoma and cholangiocarcinoma
  • Gastrointestinal cancers including gastroesophageal and colon malignancies

These trials highlight a mix of regenerative, surgical, and drug-based research, all aimed at improving control of chronic inflammation and difficult digestive cancers.

Ophthalmology, Infectious Disease, and Immune-Mediated Conditions

Additional research at Hospital Universitario Fundacion Jimenez Diaz covers eye diseases, virus diseases, and immune system diseases, including geographic atrophy, uveitic macular edema, HIV-1 infection, RSV-associated disease, and monkeypox. The main aim is to improve diagnosis, preserve vision, and test better preventive or treatment options for infectious and immune-driven conditions.

  • Retinal and inflammatory eye disease, especially geographic atrophy and uveitic macular edema
  • HIV-1 treatment and treatment-switch studies
  • Viral infections and vaccine-related research for emerging and respiratory pathogens

This portfolio shows the site’s wide clinical reach, extending beyond oncology and cardiology into vision care, infectious disease, and immune-mediated disorders where better long-term control is needed.

Site Overview

assignment
798
connected trials
corporate_fare
326
sponsors
science
746
IMPs

Activity Indicator

Last 6 months

71
Trials started
-9% vs previous period.
78
Trials started 6–12 months ago
798
Total trials linked
Highly Active
trending_downDeclining-9%
16
19
9
12
11
4
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 32 therapeutic areas and 15 of 746 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 719 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
373
Sponsors (total)
326
Active sponsors
193

Sponsor Network

Top 193 by active trials.

lock +192 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +110 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 567 other sites in Spain

description
Trial volume
798
Outperforms 98% of sites
public
Therapeutic diversity
34areas
Outperforms 98% of sites
groups
Sponsor diversity
326sponsors
Outperforms 99% of sites

Therapeutic Area Benchmark — Spain

Select a therapeutic area to compare against other sites in Spain.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Spain

Market Share

Country: Spain

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Hospital Universitario Fundacion Jimenez Diaz

lock Showing 1 of 798 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
(20289) A Phase 2 Basket Study of the Oral TRK Inhibitor larotrectinib in Subjects with NTRK Fusion-Positive TumorsBayer AG, Bayer Consumer Care AGPhase IINot RecruitingJun 2016Sep 2025

IMP list

lock Showing 1 of 746 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Pembrolizumab65Unknown2018-08-242026-06-03

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.